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Iron status in patients receiving erythropoietin for dialysis.associated
anemia. Adequate body iron stores are crucial to assuring rapid and
complete response to recombinant human erythropoietin (rHuEPO). In
the present study, markers of iron storage were examined in 27 patients
with normochromic, normocytic anemia undergoing acute rHuEPO
(150 to 300 U/kg t.i.w.) treatment for anemia. We calculated projected
iron needed for new hemoglobin synthesis from the difference between
initial and target hemoglobin concentrations, initial iron reserves avail-
able from initial serum ferritin levels, and net projected surplus or
deficit from the difference between needs and reserves. Of 22 patients
predicted to develop iron deficiency (mean projected deficit 268 70
mg), 20 developed evidence of exhausted iron stores (transferrin %sat
< 16 or ferritin < 30 gig/liter) before reaching target hemoglobin; two
predicted to become deficient (projected deficit < 100 mg) did not; and
all five predicted to avoid iron deficiency (mean projected surplus 177
20 mg) remained iron replete. During acute rHuEPO therapy net body
iron balance remained neutral in patients receiving no iron supplements
and increased 5 mg/kg in patients prescribed oral ferrous sulfate.
However, in patients given iron dextran i.v. less than 60% of elemental
iron administered became measurable as iron stores or usable for
hemoglobin synthesis.
Accurate assessment of iron stores in patients undergoing
hemodialysis is notoriously difficult [I], in part because pertur-
bations in red cell production and destruction cause many
indices of internal iron balance to be uninterpretable, and in
part because red cell transfusions, intercurrent disease and
intermittent blood loss render external iron balance unstable.
Recent introduction of effective therapy for dialysis-associ-
ated anemia [2] has heightened the need for reliable markers of
iron sufficiency. Rapid correction of anemia by recombinant
human erythropoietin (rHuEPO) demands abundant iron for
new hemoglobin synthesis. If available body iron reserves are
inadequate, optimal therapeutic response to rHuEPO is threat-
ened by iron deficiency.
To develop an accurate gauge of body iron reserves in
patients undergoing erythropoietin replacement therapy, we
examined serum ferritin, serum iron, and transferrin saturation,
as well as serum iron increment after defcroxamine iron chal-
lenge test [3J, before rHuEPO therapy in 27 chronic hemodial-
ysis patients.
Methods
Patient selection
Twenty-seven patients selected to receive rHuEPO (150 to
300 U/kg) for acute treatment of anemia were hemodialyzed
three times a week, ambulatory, clinically stable, 33 to 76 years
old, and evidenced hematocrit <30 and none of the following:
GI blood loss, hemolysis, neutropenia, thrombocytopenia,
Coombs test positivity, active liver disease, concomitant andro-
gen or chelation therapy or red cell hypochromia or microcy-
tosis. Studies were undertaken after signed informed consent
was obtained according to protocol approved by the Human
Subjects Committee of the University of Arizona. Before
inclusion in study, patients with transferrin saturation <20% or
ferritin <100 pg/liter received iron dextran (Fison Corp., Bed-
ford, Massachusetts, USA) equivalent to 500 to 1000 mg
elemental iron as 100 mg i.v. post-dialysis three times a week.
Iron deficiency detected after initiating rHuEPO was treated by
iron supplementation with 325 to 975 mg FeSO4 p.o. daily, iron
dextran iv. as above, or both. For each such patient, selection
of route, dose, and duration of supplemental iron therapy was
specified not by experimental protocol but by the primary
attending physician.
Dtferoxarnine challenge lest
Immediately after hemodialysis each patient received a 40
mg/kg i.v. infusion of deferoxamine (Desferol, Ciba-Geigy) over
60 minutes. Blood drawn before and 1, 24 and 48 hours after
infusion was immediately separated by centrifugation, and
serum stored at —20°C in capped polycarbonate tubes placed in
ice-filled sealed plastic bags to prevent dehydration. Total
serum iron was determined by a coulometric method and the
difference between pre-DFO and maximum post-DFO iron
levels recorded as stimulated (delta) iron [3].
Erythropoietin therapy
Received for publication April 25, 1988
and in revised form September 22, 1988
© 1989 by the International Society of Nephrology
Beginning 10 to 14 days after DFO infusion each patient
received rHuEPO ISO or 300 U/kg i.v. post-dialysis until
hematocrit reached or exceeded 35 (corresponding to hemoglo-
bin approximately 11.55 g/dl). In each patient, hematologic
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indices including hemoglobin, hematocnt, and reticulocyte
count were measured thrice weekly and serum iron, TIBC
(American Monitor, Indianapolis, Indiana, USA) and ferritin
(by 2-layer immunoradiometric method, Dade Clinical Assays,
Cambridge, Massachusetts, USA) were examined every 14
days.
Estimates of iron stores
By a method previously described [4] and modified for the
current study, we estimated iron status by distinguishing iron
reserves available before rHuEPO (as reflected by the serum
ferritin) from iron needed for hemoglobin synthesis to amelio-
rate anemia (as reflected by the difference between pre- and
post-treatment blood hemoglobin concentrations). Formula-
tions which follow are based on evidence gained by quantitative
phlebotomy that 1 jig serum ferritin per liter corresponds to 8 to
10 mg storage iron; that the relationship between ferritin and
iron stores is nonlinear for high ferritin levels; and that a rise of
1.0 gldl in circulating hemoglobin uses 150 mg storage iron [4].
Specifically, available iron reserves were calculated as fol-
lows:
iron reserves (mg) 400 X [log(ferritin) — log(30)] [A]
where log is the logarithm to the base 10, ferritin is the
pretreatment serum ferritin level in jig/liter, 400 is an empiric
constant, and 30 is the threshold ferritin level for iron deficiency
in dialysis patients [5].
Projected iron needs for new hemoglobin synthesis were
calculated as follows:
iron needs (mg) = 150 x (11.55 — Hb1) [B]
where Hb, is the initial pretreatment hemoglobin in g/dl, 11.55
is the target hemoglobin corresponding to hematocrit of 35, and
ISO reflects the assumption that I g/dl circulating hemoglobin
corresponds to 150 mg body iron.
Subtracting needs from reserves yields net body iron stores
projected at completion of therapy (that is, target hemoglobin
11.55 g!dl):
iron reserves — iron needs = net projected iron stores [C]
Thus, patients were predicted to become iron deficient if
calculated iron needs exceeded available iron reserves, and
remained iron replete if reserves exceeded needs.
Criteria for iron deficiency
Patients were judged iron deficient during treatment if trans-
femn iron saturation was 16% or serum ferritin was 30 jig!
liter.
Results
Of 22 patients whose predicted iron needs exceeded calcu-
lated available iron reserves (mean projected deficit 268 70
mg), 20 developed iron deficiency before reaching target hemo-
globin (Fig. 1). Of the remaining seven patients, two predicted
to become deficient (projected deficit < 100 mg) as well as all
five predicted to complete therapy with a net iron surplus
remained iron replete (mean projected surplus 177 20 mg, P
<0.01 compared to predicted iron deficit).
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Fig. 1. Available iron stores compared to predicted iron needs in 27
patients preparing to receive rHuEPO therapy. Only two patients
predicted to become iron deficient (coordinates fall below line of
identity) were misclassified by initial calculations. Symbols are: (S)
remained repleat; (0) became deficient.
Thus, formulations based on noninvasive assessment of body
iron reserves and treatment-stimulated iron needs are sensitive
(100%), specific (71%), efficient (93%) and show high positive
(91%) and negative (100%) predictive value in estimating ade-
quacy of iron stores before rHuEPO.
Although the relationship between stimulated (delta) iron
after deferoxamine infusion test and logarithm of femtin con-
centration (r = 0.539, P = 0.01) was statistically significant,
delta iron showed no discernible predictive value when plotted
against projected iron needs (Fig. 2).
To aid in assessment of iron stores before rHuEPO therapy
we developed a nomogram from which it is possible to quantify
iron deficit or predict iron surplus when only pretreatment
hemoglobin and ferritin levels (Fig. 3) are known. The nomo-
gram was constructed by solving equation [A] above for fern-
tin, as follows:
ferritin = 10 x (log3O + iron reservcs)/400 [DI
then rearranging [C]:
iron reserves = net projected iron stores + iron needs [El
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Fig. 2. Chelarable (delta) iron showed no value in predicting iron
sufficiency or deficiency after rHuEPO therapy. Symbols are: (•)
remained repleat; (0) became deficient.
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Fig. 3. Nomogram for predicting net iron deficient or surplus in
anemic dialysis patients preparing to undergo rHuEPO therapy, as-
suming target hemoglobin is /1.6 g/dl (Hct approximately equal to 35).
To determine degree of projected iron deficit, plot initial hemoglobin
against initial ferritin concentration, locate nearest isobar and follow to
left axis to find corresponding deficit. For example, 2 patients, one with
initial hemoglobin of 7,5 and ferritin of 100, and another with 6.0 and
300, respectively, would each be predicted to need 400 mg more iron
than each has available to reach target hemoglobin.
and substituting the right side of equation [El for iron reserves
in [DJ. From the resulting equation, each diagonal or isobar of
the nomogram, corresponding to 100 mg increments of iron
deficit, was constructed by varying values for initial hemoglobin
concentration while keeping iron deficit level constant, calcu-
lating the result (ferritin), and connecting the points. To illus-
trate the use of the nomogram, results from our 27 patients are
shown (Fig. 4).
'l'o examine the relationship between body iron balance and
response to iron replacement during r}IuEPO therapy, we
determined net projected iron stores at intervals after oral or no
iron supplement among patients who developed iron deficiency,
and expressed the calculated change in net projected stores per
day as daily iron balance (Table I). Patients were included if the
length of observation from onset of rHuEPO therapy was at
least 50 but no longer than 90 days without blood loss, change
in oral iron prescription, or administration of i.v. iron. Patients
with severe iron overload were excluded from analysis: maxi-
mum serum ferritin among selected patients before rHuEPO
—
Although there was no relationship between iron balance and
dose of oral iron supplement (325 to 975 mg/day FeSO4), those
patients prescribed oral iron showed higher projected iron
stores and daily iron balance than those who received no iron at
all. Indeed, patients who received no iron supplements showed
no significant change in projected iron stores during the period
of observation; although mean projected iron stores increased
slightly, this difference was not significant by paired 1-test. Two
of the eight patients prescribed oral iron, as well as five of the
eight unsupplemented patients, later required parenteral iron
before achieving target hemoglobin or converting to mainte-
nance (chronic) rHuEPO therapy.
Projected iron status was also calculated from values of
hemoglobin and ferritin measured before rl-IuEPO and 54 to 93
days after 500 mg i.v. iron dextran in six patients who became
deficient during rHuEPO therapy (Table 2). For each patient,
none of whom received oral iron during the period of observa-
tion, net projected iron stores were calculated before rHuEPO
and after iron therapy, the difference between the two values
was determined, and the results were compared to the dose of
elemental iron administered. Results showed that although
projected iron stores increased in each patient after i.v. iron
dextran, the portion of parenterally administered iron which
later became measurable as new hemoglobin or storage iron
was incomplete and highly variable. Moreover, all seven pa-
tients who had received 500 to 1000 mg parenteral iron before
rHuEPO became iron deficient during rHuEPO therapy even
though in each case the parenteral iron dose administered
exceeded the iron deficit initially projected.
Discussion
Our results confirm that iron deficiency is a common compli-
cation of erythropoietin replacement therapy for dialysis-asso-
ciated anemia. Among severely anemic patients, only those
who evidenced transfusional iron overload before rHuEPO
escaped iron deficiency during acute treatment.
The potential for iron deficiency to block or slow response to
rHuEPO heightens the need to assess body iron reserves
accurately before correcting anemia. Our approach to predict-
ing iron sufficiency for rHuEPO therapy requires available iron
stores, reflected by the serum ferritin level, to be weighed
against anticipated iron needs for heightened hemoglobin syn-
thesis. Although the underlying calculations required are nei-
ther new nor complex, to our knowledge modification of these
mathematical concepts to estimating iron stores before correct-
ing dialysis-associated anemia has not been previously at-
tempted. Indeed, the predictive value of the method supports
the conclusion that the logarithmic transformation of the serum
ferritin reliably reflects tissue iron stores over a wide range of
values. Given concern that the relationship between iron stores
and serum ferritin may lose accuracy above ferritin levels of
1000 jig/liter [4J, estimates of body iron in patients suffering
substantial iron overload should be regarded as qualitative.
However, precise quantification of iron stores in such patients
is not imperative, since their risk of acquiring rHuEPO-associ-
ated iron deficiency is low.
Our experience suggests, by contrast, that the deferoxamine
challenge test, although reportedly helpful in assessing iron
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Fig. 4. Prediction of iron surplus and quantification of iron deficit is
illustrated with data from patients in the current study. Two patients
who were misclassified showed projected iron deficit less than 100 mg
Van Wyck ci a!: Fe in dialysis-associated anemia 715
Table 1. Effect of oral iron supplements on projected iron stores calculated before rHuEPO and after an interval of rHuEPO therapy
Prescribed
FeSO4
supplement
mg/d N
Follow-up
interval
days
.
Hemoglobin g/dl
—
Ferr.. .itin sg/!,zer .Projected .iron stores mg
Daily
iron
balance
mg/dayBefore After P Before After P
-
Before After P
325—975 8 mean 68.3 7.5 11.5 0.001 376.4 64.5 0.055 —233.3 96.4 0.001 4.6
SD 10.5 1.1 0.9 418.0 52.9 172.6 221.9 3.0
None 8 mean 64.9 8.0 10.7 0.001 309.5 91.3 0.004 —84.3 —23.0 0.296 1.1
SD 7.2 1.0 0.8 201.4 154.5 193.2 134.0 2.6
Pb 0.517 0.399 0.065 0.462 0.462 0.248 0.401 0.027
a Paired t-test
' Mann-Whitney U test
burden in transfusional iron overload, does not appear useful in
identifying patients at risk for iron deficiency acquired during
rHuEPO therapy.
The usefulness of our approach lies not only in predicting iron
status after acute rHuEPO therapy but also in guiding iron
supplementation. Our results suggest that patients prescribed
oral iron show positive iron balance during acute rHuEPO
therapy, consistent with previous information that intestinal
iron absorption is not impaired in dialysis patients [5]. The
observation that degree of iron balance among these patients
bears no relationship to dose prescribed may arise from non-
compliance, since doses of FeSO4 above 325 mg/day are not
well tolerated, or from imprecision of body iron determination.
Whatever the explanation, oral iron therapy is nevertheless
frequently inadequate to avert rHuEPO-induced iron defi-
ciency.
Previous estimates of storage iron in patients with dialysis-
associated anemia show that untreated hemodialysis patients
suffer a net iron deficit of approximately I mg per day through
dialyzer and 0! blood loss [6]. Our finding that patients who
received no iron supplements maintained neutral iron balance
suggests that patients receiving acute therapy with rHuEPO
enjoy avid dietary iron absorption, perhaps stimulated by
rHuEPO-induced reticulocytosis, sufficient to match ongoing
blood loss. Alternatively, it is also possible that the mathemat-
ical relationships between body iron stores, hemoglobin and
ferritin which provide predictive value under equilibrium con-
ditions falsely overestimate iron stores during acute correction
of anemia.
Even when oral iron supplements are prescribed, gains in
iron balance are slow, so that parenteral iron therapy may be
unavoidable if a rapid response to rHuEPO is required. How-
ever, determination of iron replacement doses should take into
account our estimate that less than 50% of elemental iron
administered as iron dextran becomes measurable as iron
reserves or accessible for erythropoiesis. These findings are in
keeping with previous experience with iron dextran therapy in
non-azotemic patients with iron deficiency anemia. In these
patients, a major portion of parenterally administered colloidal
iron is deposited in a reticuloendothelial storage pool charac-
tenzed by inaccessibility to deferoxamine chelation and a
delivery rate to the marrow so slow that utilization for rapid
correction of anemia is effectively precluded [7].
In order to discuss iron supplementation with rHuEPO ther-
apy it is useful to distinguish iron deficiency hematopoiesis,
characterized by absence of marrow iron, low serum ferritin
and (most reliably) transferrin saturation less than 16%, from
iron deficiency anemia, marked by a hypoproliferative bone
marrow and hypochromic, microcytic red cell indices. In our
patients, evidence of iron deficiency hematopoiesis prompted
oral or parenteral iron supplementation before the onset of
progressive anemia or failure to achieve target hemoglobin.
Non-azotemic patients with established iron lack anemia re-
spond equally well to oral as to parenteral therapy, probably
because the contracted, quiescent erythron after long-term iron
deficiency cannot make use of high doses of exogenous iron [8].
During acute rHuEPO therapy, on the other hand, newly
acquired iron deficiency hematopoiesis may benefit from vigor-
Table 2. Projected iron stores in patients before rHuEPO and after iv iron (500 mg)
chronic rHuEPO therapy
for treatment of iron deficiency acquired during acute and
Days elapsed from before
rHuEPO to
Last acute
rHuEPO 1st dose Last
Post-iron
follow-up Hemoglobin gld!interval — Ferritin pg/!iter
Projected iron
stores mg
— Recovery
Case Rx i.v. iron follow-up days Before After Before After Start End %
JO 84 84 138 54 7.4 9.4 603 339 —101.2 98.7 40.0
JS 42 46 100 54 9.1 11.2 181 122 —55.3 191.2 49.3
FV 42 52 131 79 6.7 8.7 233 179 —371.4 —117.2 50.8
PV 65 65 147 82 5.7 8.9 188 157 —558.7 —110.0 89.7
BC 81 70 163 93 9.2 11.2 121 55 —110.2 52.8 32.6
JV 84 70 138 68 7.9 11.6 278 123 —160.7 252.6 82.7
Mean 66.3 64.5 136.2 71.7 7.7 10.2 267.3 162.5 —226.3 61.4 57.5
SD 18.4 12.5 19.1 14.5 1.2 1.2 157.7 87.8 179.9 139.1 21.3
P (paired t-test) <0.001 0.034 0.002
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ous replacement of iron stores while the erythron still remains
active, thereby maintaining rHuEPO-induced new hemoglobin
synthesis, shortening acute treatment intervals, and minimizing
cumulative rHuEPO dosage.
The rapid fall in serum ferritin after rHuEPO suggests that a
secondary benefit of erythropoietin replacement therapy may
be reversal of parenchymal iron overload without exogenous
chelation therapy. Hemosiderosis in dialysis patients [9, 101,
commonly secondary to frequent red cell transfusions and often
characterized by liver disease and endocrine abnormalities, has
been treated in the past with chronic chelation by deferoxamine
[11]. In dialysis patients, rHuEPO offers the potential not only
to avert iron loading by avoiding transfusion but also to remove
iron excess by supporting phlebotomy.
In short, our results demonstrate that body iron reserves can
be assessed, iron needs for new hemoglobin synthesis pre-
dicted, and appropriate iron replacement therapy planned in
patients receiving rHuEPO for correction of dialysis-associated
anemia.
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